Participants are randomly placed into one of the two groups, receive the assigned treatment, and then are followed for several months to watch for changes in the disease and to record how they feel. The main result that researchers will look at is the length of time before the disease progresses, known as progression-free survival. They will also examine other outcomes such as how long patients live overall (overall survival), how their daily wellbeing is affected (quality of life), and whether a scoring system used during surgery (intraoperative pleural disease dissemination score) can predict future outcomes. The study continues until enough information is gathered to compare the two treatment strategies.

The main goal of the trial is to find out whether the medication can slow the increase in the size of the damaged areas of the retina. The study is designed so that participants are randomly assigned to receive either the active drug or the placebo, and neither the participants nor the study staff will know which treatment is given. The trial will last about two years, with regular clinic visits for assessments.

During the study, participants will take one capsule each day and attend scheduled visits where several eye tests are performed. A special camera called FAF will take pictures that highlight unhealthy retinal tissue, while an imaging technique known as OCT will create cross‑sectional views of the eye’s layers. Vision will be measured using a standard eye chart (ETDRS) to determine BCVA, and low‑light reading ability will also be checked. Reading speed will be evaluated with two tests, IReST and MNRead. Sensitivity of the retina will be mapped with microperimetry, and participants will complete questionnaires such as the NEI-VFQ-25 to report how the condition affects daily activities.

The purpose of the study is to see how well Concizumab works in preventing bleeding episodes compared to the previous treatment the children were receiving. The study will involve children who have not used Concizumab before. Participants will receive regular injections of Concizumab over a period of time, and the number of bleeding episodes they experience will be monitored and compared to their previous treatment.

Throughout the study, researchers will also keep track of any side effects or reactions to the medication, such as injection site reactions or the development of antibodies against Concizumab. The study aims to provide valuable information on the safety and effectiveness of Concizumab in managing bleeding episodes in young children with hemophilia.

The purpose of the study is to see how well Selpercatinib works compared to the other two treatments in patients who have not previously been treated with kinase inhibitors. Participants in the study will be randomly assigned to receive either Selpercatinib, Cabozantinib, or Vandetanib. The study will monitor the progress of the cancer and how it responds to the treatment over time. The treatments are taken orally, meaning they are swallowed in the form of a pill or capsule.

The study will take place over a period of time, and participants will have regular check-ups to monitor their health and the status of their cancer. The goal is to determine which treatment is most effective in slowing down or stopping the growth of the cancer. This information could help improve treatment options for people with RET-mutant medullary thyroid cancer in the future.

Participants will receive a series of injections over a period of several weeks, with regular visits to the clinic where doctors will ask about eye symptoms, quality of life, and ability to perform daily activities. Simple questionnaires will be used to measure changes in eye muscle strength and overall well‑being. The study will also monitor any side effects that may occur during the treatment period.

The purpose of the study is to describe the safety profile of the PG4 vaccine. Infants receive a single dose of either the study vaccine or the comparison vaccine and are then observed for a short time after the injection, followed by scheduled visits to check their health over the next weeks.

Researchers will watch for common side effects such as redness, swelling, pain at the injection site, fever, reduced appetite, irritability, or increased sleep. Any side effects, known as adverse events, and any serious side effects that require medical attention, called serious adverse events, will be recorded and reviewed.

The purpose of the study is to compare how well BNT324 works against docetaxel in slowing disease progression and extending survival. Participants are randomly assigned to one of the two groups and receive the assigned medication in cycles, typically every three weeks, with treatment continuing until the disease worsens, side effects become too severe, or the planned treatment period ends.

During the trial, patients undergo regular imaging scans to check for changes in tumor size, blood tests to monitor prostate‑specific antigen levels, and assessments of pain and overall health. The study records how long the cancer remains stable, the time until death from any cause, and any side effects experienced.

The purpose of the trial is to evaluate the safety and clinical activity of the drug and to determine the appropriate dose for later studies. Participants will receive a series of injections over several weeks while doctors monitor them closely for any signs of dose limiting toxicities, adverse events or serious adverse events. Routine visits will include blood work, checks of vital signs such as blood pressure and heart rate, and an electrocardiogram (ECG) to record the heart’s electrical activity.

Additional evaluations will look at how well the cancer responds, measured by the Overall Response Rate (ORR), and will also assess how the drug behaves in the body, including its Maximum concentration (Cmax), the time it takes to reach that level (Time to Cmax (Tmax)), and the total exposure over time (Area under the curve (AUC)). These assessments help researchers understand both the effectiveness and the safety profile of the treatment.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

People in the study receive their assigned medicine at the start and then are followed for about a year. During this time they return for visits where a special scan called high resolution peripheral quantitative computed tomography—a detailed imaging test that measures the size of bone pits—checks the joints, and they fill out questionnaires about hand pain and function, including the AUSCAN and FIHOA surveys, as well as a simple pain rating called the Pain VAS. These assessments help researchers understand any changes in the bone damage and how the participants feel and use their hands over the study period.

During the 24‑week period, participants are randomly assigned to one of the two groups and neither the participants nor the study staff know which treatment is given (double‑blind). Regular visits include blood tests that measure NT-proBNP, a protein that rises when the heart is under stress, and imaging tests such as an ultrasound of the heart (echocardiogram) that assess measurements like left ventricular end-diastolic volume index, left ventricular end-systolic volume index, E/e′ ratio, global longitudinal strain and left atrial volume index. Participants also complete the Kansas City cardiomyopathy questionnaire to report symptoms and quality of life, and a routine 12‑lead Electrocardiogram is performed to check the heart’s electrical activity. Throughout the study, safety is monitored by recording any side effects and checking routine laboratory values.

The main goal is to determine which order of these medicines provides the longest overall survival, meaning the length of time a person lives after beginning treatment, while also considering factors such as side effects, quality of life, and treatment costs.

Participants will take the oral pills each day and receive the intravenous infusions at regular clinic visits according to a schedule decided by the treating doctors. Throughout the study, they will have routine medical examinations, imaging scans to see how the cancer is responding, and complete questionnaires that ask about daily wellbeing, side effects, and any financial strain. The study follows each person for months or years, recording what happens as they move from one therapy to the next, to understand which sequence works best.

The purpose of the study is to see if the combination is safe, well‑tolerated, and practical to use. Participants will start with a low amount of Trazodone that is gradually increased over several visits. After the selected dose is reached, a fixed amount of psilocybin will be taken, and the person will be monitored for about a month. During this time, doctors will check vital signs such as heart rate and blood pressure, perform simple heart tests, and run laboratory checks. They will also ask participants about any changes in mood, thoughts of self‑harm, and how they feel during the psilocybin experience. The study will also look at pharmacokinetics, which means how the body absorbs, distributes, and clears both medicines.

The purpose of the study is to determine whether adding the drug to the usual treatment, called standard of care, lowers the risk of returning to the hospital, visiting the ED, or dying after the flare‑up. After discharge, participants are randomly assigned to one of the two groups and receive injections at regular intervals while researchers check in with them through clinic visits and phone calls over several months.

Researchers will track how often participants experience another worsening of symptoms, known as an exacerbation, and will record any unplanned hospital readmissions, urgent care visits, or deaths. They will also ask participants to complete simple questionnaires that measure how the lung disease affects daily life and symptom severity. Any side effects or health problems that appear during the study will be recorded and evaluated.

During the trial, patients will start treatment and then return for regular visits where doctors will check for side effects and perform imaging scans, such as CT or MRI, to see how the tumors are changing. The scans are evaluated using a standard set of rules called RECIST, which helps doctors decide whether the cancer is responding, staying the same, or getting worse. Treatment continues as long as it is tolerated and the disease does not progress, with follow‑up visits scheduled at set intervals to monitor health and tumor size.

The purpose of the study is to determine how effectively this drug combination can delay the need for additional cancer therapy. Participants receive the study tablets for up to two years while attending regular check‑ups where doctors monitor health, side effects, and any changes in the cancer. Safety is closely watched through routine tests and reporting of any adverse effects.

The purpose of the trial is to find out whether taking colchicine each day can slow the typical decline in muscle function compared with the placebo.

Participants will be randomly assigned to receive either the colchicine tablet or the placebo tablet for about 30 weeks, followed by an optional open‑label period where all may receive the active drug. During the study, they will attend regular clinic visits where basic health checks, breathing tests, and questionnaires about daily abilities and quality of life are completed. The study ends after a total of roughly 66 weeks, at which point the collected information will be used to evaluate the medication’s effect.

Participants will take one hard capsule each day for about six months while keeping a simple diary of any swelling episodes, any other health problems, and any use of emergency treatment. Regular check‑ins with study staff will be scheduled to review the diary, assess safety, and record any side effects, known as adverse events. The overall design is open‑label and single‑arm, meaning all participants receive the same medication and know they are receiving the active treatment.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

The purpose of the study is to find out whether taking dexamethasone beforehand lowers the chance of developing interstitial lung disease in these patients. Participants will continue their usual cancer therapy, and the study will add the dexamethasone tablets for a set period. Over the next year, they will have regular doctor visits, blood tests, and lung checks to see how they are doing.

Doctors will use a special imaging test called a high-resolution thorax CT scan to get detailed pictures of the lungs and will watch for any side effects such as nausea, liver changes, cough, or shortness of breath. The study will also record overall well‑being and quality of life throughout the follow‑up period.

The purpose of the study is to evaluate how the addition of sodium valproate influences patients’ quality of life and tumor response. Participants will receive the medicines for several months, attend regular clinic visits, complete a quality‑of‑life questionnaire called EORTC QoL Q30 – HN43/ EORTC QLQ-C30, and undergo imaging scans that are assessed using the standard measurement system RECIST 1.1. The study tracks changes in daily well‑being and the size of the cancer over time.

The treatment being studied involves a combination of two medications: MK-1084 and pembrolizumab. Pembrolizumab is also known by the brand name KEYTRUDA and is given as an infusion, which means it is delivered directly into the bloodstream through a vein. MK-1084 is taken as a tablet. Some participants in the study will receive pembrolizumab with MK-1084, while others will receive pembrolizumab with a placebo, which looks like the real medication but does not contain any active ingredients. The purpose of the study is to compare the effectiveness of these two treatment combinations.

Participants in the study will receive their assigned treatment and will be monitored over a period of time to see how their cancer responds. The study will look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time participants live after starting the treatment. The study will also track any side effects experienced by participants and how the treatment affects their quality of life. This information will help researchers understand the potential benefits and risks of the new treatment combination for people with this specific type of lung cancer.

The purpose of the study is to continue providing benralizumab to individuals who have already shown benefit and to monitor its long‑term safety and how well it is tolerated. After completing the earlier trial, participants will receive regular injections of the medication for an extended period, with scheduled clinic visits where doctors check for any side effects or health changes and collect safety information. The study will end several weeks after the last dose is given.

The purpose of the study is to determine whether the experimental drug can restore a normal heart rhythm, known as sinus rhythm. In the trial, adult participants are randomly assigned to receive either the study drug or the placebo. The assigned treatment is delivered by a short intravenous infusion, and participants are observed for at least three hours to see if their heart rhythm changes from the irregular pattern to a steady one without needing additional procedures. Safety checks are performed throughout the visit, and a blood sample is taken at the end of the infusion to measure how much of the medicine is present in the body.

The purpose of the trial is to determine whether AZD8965 can reduce the loss of lung function compared with placebo, using the change in FVC (forced vital capacity, the amount of air exhaled forcefully after a deep breath) as the main measure over about 24 weeks. Participants will be screened, then randomly assigned to receive either the study drug or placebo for a six‑month period, with regular clinic visits for safety checks, blood samples, and simple breathing tests. Throughout the study, any side effects and overall health will be closely monitored.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.